Literature DB >> 8988009

Molecular recognition by cholesterol esterase of active site ligands: structure-reactivity effects for inhibition by aryl carbamates and subsequent carbamylenzyme turnover.

S R Feaster1, K Lee, N Baker, D Y Hui, D M Quinn.   

Abstract

Interactions of mammalian pancreatic cholesterol esterases from pig and rat with a family of aryl carbamates CnH2n+1NHCOOAr [n = 4-9; Ar = phenyl, p-X-phenyl (X = acetamido, bromo, fluoro, nitro, trifluoromethyl), 2-naphthyl, 2-tetrahydronaphthyl, estronyl] have been investigated, with an aim of delineating the ligand structural features which lead to effective molecular recognition by the active site of the enzyme. These carbamates inhibit the catalytic activity of CEase by rapid carbamylation of the active site, a process that shows saturation kinetics. Subsequent slow decarbamylation usually leads to full restoration of activity, and therefore aryl carbamates are transient inhibitors, or pseudo-substrates, of CEase. Structural variation of carbamate inhibitors allowed molecular recognition in the fatty acid binding and steroid binding loci of the extended active site to be probed, and the electronic nature of the carbamylation transition state to be characterized. Optimal inhibitory activity is observed when the length of the carbamyl function is n = 6 and n = 7 for porcine and rat cholesterol esterases, respectively, equivalent to eight- and nine-carbon fatty acyl chains. In contrast, inhibitory activity increases progressively as the partial molecular volume of the aromatic fragment increases. Hammett plots for p-substituted phenyl-N-hexyl carbamates indicate that the rate-determining step for carbamate inhibition is phenolate anion expulsion. Effects of the bile salt activator taurocholate on the kinetically resolved phases of the pseudo-substrate turnover of aryl carbamates were also studied. Taurocholate increases the affinity of the carbamate for the active site of cholesterol esterase in the reversible, noncovalent complex that precedes carbamylation and increases the rate constants of the serial carbamylation and decarbamylation steps. Structural variation of the N-alkyl chain and of the aryl fused-ring system provides an accounting of bile salt modulation of the fatty acid and steroid binding sites, respectively. In that pseudo-substrate turnover of aryl carbamates proceeds by a three-step mechanism that is analogous to that for rapid turnover of lipid ester substrates, these investigations illuminate details of ligand recognition by the extended active site of cholesterol esterase that are prominent determinants of the substrate specificity and catalytic power of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8988009     DOI: 10.1021/bi961677v

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  New insights in the activation of human cholesterol esterase to design potent anti-cholesterol drugs.

Authors:  Shalini John; Sundarapandian Thangapandian; Prettina Lazar; Minky Son; Chanin Park; Keun Woo Lee
Journal:  Mol Divers       Date:  2013-10-31       Impact factor: 2.943

2.  Synthesis and evaluation of a new series of tri-, di-, and mono-N-alkylcarbamylphloroglucinols as conformationally constrained inhibitors of cholesterol esterase.

Authors:  Ming-Cheng Lin; Gin-Zen Lin; Ching-In Hwang; Shuo-Yung Jian; James Lin; Yu-Fong Shen; Gialih Lin
Journal:  Protein Sci       Date:  2012-08-09       Impact factor: 6.725

3.  Stereoselective inhibition of cholesterol esterase by enantiomers of exo- and endo-2-norbornyl-N-n-butylcarbamates.

Authors:  Ming-Cheng Lin; Shyh-Jei Yeh; I-Ru Chen; Gialih Lin
Journal:  Protein J       Date:  2011-03       Impact factor: 2.371

4.  Stoichiometry and Kinetics of Sequential Dimethacrylate Enzymolysis.

Authors:  S Frukhtbeyn; K Van Dongen; J Sun
Journal:  J Dent Res       Date:  2019-08       Impact factor: 6.116

5.  Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an Alzheimer's disease mouse model.

Authors:  Philipp Spatz; Thomas Zimmermann; Sophie Steinmüller; Julian Hofmann; Tangui Maurice; Michael Decker
Journal:  RSC Med Chem       Date:  2022-06-20

6.  Interaction of the serine hydrolase KIAA1363 with organophosphorus agents: Evaluation of potency and kinetics.

Authors:  Matthew K Ross; Kim Pluta; Victoria Bittles; Abdolsamad Borazjani; J Allen Crow
Journal:  Arch Biochem Biophys       Date:  2015-11-23       Impact factor: 4.013

7.  Benzene-di-N-substituted carbamates as conformationally constrained substrate analogs of cholesterol esterase.

Authors:  S-Y Chiou; M-C Lin; M-T Hwang; H-G Chang; G Lin
Journal:  Protein J       Date:  2008-08       Impact factor: 2.371

8.  5,6-Benzoflavones as cholesterol esterase inhibitors: synthesis, biological evaluation and docking studies.

Authors:  Jatinder V Singh; Anumeet Kaur; Kavita Bhagat; Manish K Gupta; Manwinder Singh; Harbinder Singh; Preet Mohinder S Bedi
Journal:  Medchemcomm       Date:  2018-01-19       Impact factor: 3.597

9.  Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability.

Authors:  Federica Vacondio; Claudia Silva; Alessio Lodola; Alessandro Fioni; Silvia Rivara; Andrea Duranti; Andrea Tontini; Silvano Sanchini; Jason R Clapper; Daniele Piomelli; Marco Mor; Giorgio Tarzia
Journal:  ChemMedChem       Date:  2009-09       Impact factor: 3.466

10.  Probing stereoselective inhibition of the acyl binding site of cholesterol esterase with four diastereomers of 2'-N-alpha-methylbenzylcarbamyl-1, 1'-bi-2-naphthol.

Authors:  Shyh-Ying Chiou; Cheng-Yue Lai; Long-Yau Lin; Gialih Lin
Journal:  BMC Biochem       Date:  2005-09-22       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.